

Lenalidomide and Dexamethasone in Transplant-Inelig

New England Journal of Medicine

371, 906-917

DOI: [10.1056/nejmoa1402551](https://doi.org/10.1056/nejmoa1402551)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Carfilzomib, lenalidomide et dexaméthasone pour le myélome multiple en rechute : l'étude Aspire. <i>Hematologie</i> , 2014, 20, 306-307.	0.0	0
2	1st World Congress on Controversies in Multiple Myeloma (COMy) Bangkok, May 11-13 2014. <i>Hematologie</i> , 2014, 20, 276-283.	0.0	1
6	Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back. <i>Ca-A Cancer Journal for Clinicians</i> , 2014, 64, 422-444.	329.8	85
7	Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. <i>Lancet Oncology</i> , The, 2014, 15, 1503-1512.	10.7	233
8	Optimizing the treatment of multiple myeloma. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 686-688.	27.6	0
9	Advances in biology and therapy. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 628-630.	27.6	3
10	Current Treatment for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2014, 371, 961-962.	27.0	26
11	European Perspective on Multiple Myeloma Treatment Strategies in 2014. <i>Oncologist</i> , 2014, 19, 829-844.	3.7	90
12	Maintenance therapy for multiple myeloma in the era of novel agents. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 279-285.	2.5	12
13	Novel combination approaches for myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 286-293.	2.5	4
14	Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival 2" as a clinical trial end-point. <i>Haematologica</i> , 2015, 100, e328-30.	3.5	28
17	How I treat relapsed myeloma. <i>Blood</i> , 2015, 125, 1532-1540.	1.4	31
18	Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. <i>Blood</i> , 2015, 126, 1294-1301.	1.4	80
19	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood</i> , 2015, 125, 2068-2074.	1.4	586
20	New prognostic tools for myeloma. <i>Blood</i> , 2015, 125, 2014-2015.	1.4	7
21	How I treat fragile myeloma patients. <i>Blood</i> , 2015, 126, 2179-2185.	1.4	63
22	Health-related quality of life in patients with multiple myeloma - does it matter?. <i>Haematologica</i> , 2015, 100, 704-705.	3.5	36
23	Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years. <i>Haematologica</i> , 2015, 100, 1340-1349.	3.5	43

#	ARTICLE	IF	CITATIONS
24	Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies. <i>Rare Cancers and Therapy</i> , 2015, 3, 47-68.	0.2	14
25	Bendamustine, bortezomib and prednisone for the treatment of newly diagnosed multiple myeloma patients: results of a prospective phase 2 Spanish/Pethema trial. <i>Haematologica</i> , 2015, 100, 1096-102.	3.5	19
26	Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma. <i>British Journal of Haematology</i> , 2015, 171, 453-462.	2.5	27
27	Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent. <i>Experimental Hematology and Oncology</i> , 2015, 5, 1.	5.0	6
28	Lenalidomide is safe and active in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2015, 90, 1055-1059.	4.1	23
29	Consolidation and maintenance in de novo first-line multiple myeloma with modern agents. <i>International Journal of Hematologic Oncology</i> , 2015, 4, 9-22.	1.6	1
30	Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide. <i>Haematologica</i> , 2015, 100, 826-833.	3.5	76
31	Expanding role of lenalidomide in hematologic malignancies. <i>Cancer Management and Research</i> , 2015, 7, 105.	1.9	29
32	Multiple Myeloma: From Front-Line to Relapsed Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e504-e511.	3.8	43
34	Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study. <i>Haematologica</i> , 2015, 100, 385-391.	3.5	26
35	Lenalidomide: A Review of Its Continuous Use in Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Stem-Cell Transplantation. <i>Drugs and Aging</i> , 2015, 32, 409-418.	2.7	12
36	Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma. <i>Future Oncology</i> , 2015, 11, 1643-1658.	2.4	0
37	Downregulation of myeloma-induced ICOS-L and regulatory T cell generation by lenalidomide and dexamethasone therapy. <i>Cellular Immunology</i> , 2015, 297, 1-9.	3.0	19
38	Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b/2 dose-escalation study. <i>Lancet Haematology</i> , 2015, 2, e516-e527.	4.6	140
39	Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma. <i>Blood Cancer Journal</i> , 2015, 5, e363-e363.	6.2	36
40	Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib+melphalan+prednisone in the phase III VISTA study. <i>American Journal of Hematology</i> , 2015, 90, 314-319.	4.1	58
41	Multiple myeloma: is a shift toward continuous therapy needed to move forward?. <i>Expert Review of Hematology</i> , 2015, 8, 253-256.	2.2	9
42	Managing multiple myeloma in the over 70s: A review. <i>Maturitas</i> , 2015, 80, 148-154.	2.4	6

#	ARTICLE	IF	CITATIONS
43	Promising therapies in multiple myeloma. <i>Blood</i> , 2015, 126, 300-310.	1.4	86
45	An update on the use of lenalidomide for the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1865-1877.	1.8	9
46	Management of Elderly Patients with Plasma Cell Myeloma. <i>Drugs and Aging</i> , 2015, 32, 427-442.	2.7	1
47	Optimizing quality of life in multiple myeloma patients: current options, challenges and recommendations. <i>Expert Review of Hematology</i> , 2015, 8, 355-366.	2.2	23
48	Is more better in myeloma? Treatment intensity and outcome in newly diagnosed myeloma patients. <i>Memo - Magazine of European Medical Oncology</i> , 2015, 8, 22-25.	0.5	1
49	Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. <i>Blood</i> , 2015, 125, 3100-3104.	1.4	47
50	Frontline therapy of multiple myeloma. <i>Blood</i> , 2015, 125, 3076-3084.	1.4	244
51	The Role of Pre-Transplant Induction Regimens and Autologous Stem Cell Transplantation in the Era of Novel Targeted Agents. <i>Drugs</i> , 2015, 75, 367-375.	10.9	5
52	Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma. <i>Current Medical Research and Opinion</i> , 2015, 31, 1105-1115.	1.9	34
53	The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. <i>Future Oncology</i> , 2015, 11, 1153-1168.	2.4	25
54	Current therapeutic strategies for multiple myeloma. <i>International Journal of Clinical Oncology</i> , 2015, 20, 423-430.	2.2	22
55	The Value of Patient Reported Outcomes and Other Patient-Generated Health Data in Clinical Hematology. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 213-224.	2.3	17
56	Cytogenetic Alterations in Multiple Myeloma: Prognostic Significance and the Choice of Frontline Therapy. <i>Cancer Investigation</i> , 2015, 33, 496-504.	1.3	11
57	A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma. <i>Cancer</i> , 2015, 121, 3622-3630.	4.1	39
58	An update in treatment options for multiple myeloma in nontransplant eligible patients. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1945-1957.	1.8	3
59	Clinical treatment of newly diagnosed multiple myeloma. <i>Expert Review of Hematology</i> , 2015, 8, 595-611.	2.2	13
60	Novel Induction Regimens in Multiple Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 388-394.	2.3	2
61	Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2015, 33, 3459-3466.	1.6	138

#	ARTICLE	IF	CITATIONS
62	Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond. <i>Current Opinion in Cell Biology</i> , 2015, 37, 61-67.	5.4	18
63	Improved understanding of disease biology and treatment. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 71-72.	27.6	6
64	Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial. <i>Haematologica</i> , 2015, 100, e56-e59.	3.5	34
65	Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 372, 142-152.	27.0	1,144
66	First line vs delayed transplantation in myeloma: Certainties and controversies. <i>World Journal of Transplantation</i> , 2016, 6, 321.	1.6	8
67	The Danish National Multiple Myeloma Registry. <i>Clinical Epidemiology</i> , 2016, Volume 8, 583-587.	3.0	38
68	Assessment and monitoring of patients receiving chemotherapy for multiple myeloma: strategies to improve outcomes. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2016, 6, 21.	2.7	2
69	Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6037-6048.	2.0	15
70	Next-Generation Sequencing Informing Therapeutic Decisions and Personalized Approaches. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e442-e448.	3.8	8
71	Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis. <i>BioMed Research International</i> , 2016, 2016, 1-17.	1.9	17
72	The Diagnosis and Treatment of Multiple Myeloma. <i>Deutsches A&#x0308;rztblatt International</i> , 2016, 113, 470-6.	0.9	129
73	Comparing efficacy and survivals of initial treatments for elderly patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 121-128.	2.0	12
74	Cost-effectiveness of bortezomib for multiple myeloma: a systematic review. <i>ClinicoEconomics and Outcomes Research</i> , 2016, 8, 137.	1.9	11
75	Multiple myeloma in the very elderly patient: challenges and solutions. <i>Clinical Interventions in Aging</i> , 2016, 11, 423.	2.9	28
76	Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression. <i>Annals of Hematology</i> , 2016, 95, 1645-1651.	1.8	4
77	Novel agents in the treatment of multiple myeloma: a review about the future. <i>Journal of Hematology and Oncology</i> , 2016, 9, 52.	17.0	140
78	Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1127-1136.	10.7	128
79	Early mortality in multiple myeloma: the time-dependent impact of comorbidity: A population-based study in 621 real-life patients. <i>American Journal of Hematology</i> , 2016, 91, 700-704.	4.1	28

#	ARTICLE	IF	CITATIONS
80	Optimal treatment strategies in myeloma: An argument against maintenance therapy after autologous stem cell transplantation. <i>Seminars in Oncology</i> , 2016, 43, 714-717.	2.2	1
81	Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. <i>Blood</i> , 2016, 128, 2415-2422.	1.4	51
82	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. , 2016, 4, 90.		17
83	Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. <i>Blood Cancer Journal</i> , 2016, 6, e506-e506.	6.2	68
84	Next-generation multiple myeloma treatment: a pharmacoeconomic perspective. <i>Blood</i> , 2016, 128, 2757-2764.	1.4	63
85	Sequencing of nontransplant treatments in multiple myeloma patients with active disease. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 495-503.	2.5	6
86	Myeloma: management of the newly diagnosed high-risk patient. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 485-494.	2.5	19
87	Specialty pharmacy for hematologic malignancies. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 797-809.	1.0	13
88	Treatment of relapsed and refractory multiple myeloma. <i>Haematologica</i> , 2016, 101, 396-406.	3.5	132
89	Nuances in the Management of Older People With Multiple Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 241-251.	2.3	11
90	Update of thrombosis in multiple myeloma. <i>Thrombosis Research</i> , 2016, 140, S76-S80.	1.7	40
91	Thromboprophylaxis in multiple myeloma patients treated with lenalidomide – A systematic review. <i>Thrombosis Research</i> , 2016, 141, 84-90.	1.7	36
92	Innovations in treatment and response evaluation in multiple myeloma. <i>Haematologica</i> , 2016, 101, 518-520.	3.5	2
93	Oral ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 374, 1621-1634.	27.0	861
94	Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2016, 127, 1102-1108.	1.4	78
95	Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM. <i>Blood</i> , 2016, 127, 420-425.	1.4	51
96	Together for better?. <i>Blood</i> , 2016, 127, 375-376.	1.4	3
97	Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. <i>Blood</i> , 2016, 127, 1109-1116.	1.4	102

#	ARTICLE	IF	CITATIONS
98	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. <i>Blood</i> , 2016, 127, 2955-2962.	1.4	686
99	Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2016, 67, 21-37.	2.8	49
100	Optimizing Treatment for Elderly Patients With Newly Diagnosed Multiple Myeloma: A Personalized Approach. <i>Journal of Clinical Oncology</i> , 2016, 34, 3600-3604.	1.6	18
101	Combination therapeutics in complex diseases. <i>Journal of Cellular and Molecular Medicine</i> , 2016, 20, 2231-2240.	3.6	76
102	Concise review Treatment of multiple myeloma in the very elderly: How do novel agents fit in?. <i>Journal of Geriatric Oncology</i> , 2016, 7, 383-389.	1.0	10
103	Treatment of Newly Diagnosed Elderly Multiple Myeloma. <i>Cancer Treatment and Research</i> , 2016, 169, 123-143.	0.5	9
104	Multiple myeloma: 2016 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2016, 91, 719-734.	4.1	366
105	The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution. <i>Cancer Medicine</i> , 2016, 5, 500-505.	2.8	5
106	Multiple myeloma: patient outcomes in real-world practice. <i>British Journal of Haematology</i> , 2016, 175, 252-264.	2.5	220
107	Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study. <i>Cancer Science</i> , 2016, 107, 653-658.	3.9	12
108	Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2016, 91, 101-108.	4.1	19
109	Myeloma today: Disease definitions and treatment advances. <i>American Journal of Hematology</i> , 2016, 91, 90-100.	4.1	142
110	Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. <i>Immunological Reviews</i> , 2016, 270, 95-112.	6.0	280
111	Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up. <i>Blood Cancer Journal</i> , 2016, 6, e466-e466.	6.2	17
112	Is Maintenance Therapy for Everyone?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S139-S144.	0.4	4
113	Lenalidomide long-term neurotoxicity. <i>Neurology</i> , 2016, 87, 1161-1166.	1.1	31
114	Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial. <i>Haematologica</i> , 2016, 101, 1398-1406.	3.5	28
115	Progress and Paradigms in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2016, 22, 5419-5427.	7.0	142

#	ARTICLE	IF	CITATIONS
116	Integration of Novel Agents into the Care of Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2016, 22, 5443-5452.	7.0	36
117	Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study. <i>Haematologica</i> , 2016, 101, 1390-1397.	3.5	62
118	Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials. <i>Annals of Hematology</i> , 2016, 95, 2033-2041.	1.8	27
119	The role of maintenance therapy in multiple myeloma. <i>Blood Cancer Journal</i> , 2016, 6, e485-e485.	6.2	29
120	Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries. <i>Scientific Reports</i> , 2016, 6, 22084.	3.3	15
122	Management of high-risk Myeloma: an evidence-based review of treatment strategies. <i>Expert Review of Hematology</i> , 2016, 9, 753-765.	2.2	4
123	Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 3609-3617.	1.6	71
124	Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program. <i>BMC Cancer</i> , 2016, 16, 46.	2.6	1
125	Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 173-182.	2.3	17
126	Are maintenance and continuous therapies indicated for every patient with multiple myeloma?. <i>Expert Review of Hematology</i> , 2016, 9, 743-751.	2.2	13
127	Prediction of patients with multiple myeloma eligible for second- or third-line treatment in France. <i>Annals of Hematology</i> , 2016, 95, 1307-1313.	1.8	2
128	An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide+dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM). <i>American Journal of Hematology</i> , 2016, 91, 806-811.	4.1	9
129	Favorable prognostic impact of <i>RAS</i> mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: a single center perspective. <i>Leukemia and Lymphoma</i> , 2016, 57, 226-229.	1.3	8
130	Myeloma. , 2016, , 89-100.		0
131	Connect MMÂ® – the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide. <i>Leukemia and Lymphoma</i> , 2016, 57, 2228-2231.	1.3	21
132	ENDEAVOR to change treatment for multiple myeloma?. <i>Lancet Oncology</i> , The, 2016, 17, 2-3.	10.7	1
133	Oral ixazomib maintenance therapy in multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 21-32.	2.4	6
134	Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible. <i>Annals of Hematology</i> , 2016, 95, 271-278.	1.8	27

#	ARTICLE	IF	CITATIONS
135	Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	6.3	49
136	Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. <i>Haematologica</i> , 2016, 101, 363-370.	3.5	33
137	Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 129-138.	0.4	68
138	Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 127-136.	2.3	20
139	Is it possible to cure myeloma without allogeneic transplantation?. <i>Transfusion and Apheresis Science</i> , 2016, 54, 63-70.	1.0	10
140	Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1776-1780.	1.3	3
141	A retrospective study of direct cost to patients associated with the use of oral oncology medications for the treatment of multiple myeloma. <i>Journal of Medical Economics</i> , 2016, 19, 397-402.	2.1	17
142	The Shreveport Myeloma Experience: Survival, Risk Factors and Other Malignancies in the Age of Stem Cell Transplantation. <i>Acta Haematologica</i> , 2016, 135, 146-155.	1.4	7
143	Price, value, and the cost of cancer drugs. <i>Lancet Oncology</i> , The, 2016, 17, 3-5.	10.7	23
144	Primary failure of bortezomib in newly diagnosed multiple myeloma – understanding the magnitude, predictors, and significance. <i>Leukemia and Lymphoma</i> , 2016, 57, 1382-1388.	1.3	10
145	Multiple Myeloma: Diagnosis and Treatment. <i>Mayo Clinic Proceedings</i> , 2016, 91, 101-119.	3.0	473
146	New pharmacotherapy options for multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 181-192.	1.8	17
147	Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma. <i>Journal of Medical Economics</i> , 2016, 19, 243-258.	2.1	26
148	Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma in Older Adults. <i>Clinics in Geriatric Medicine</i> , 2016, 32, 191-205.	2.6	4
149	Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States. <i>Current Medical Research and Opinion</i> , 2016, 32, 95-103.	1.9	80
150	Infectious complications in patients with newly diagnosed multiple myeloma: A complication from the past?. <i>Leukemia and Lymphoma</i> , 2016, 57, 258-268.	1.3	6
151	A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2017, 58, 153-161.	1.3	29
152	Management of multiple myeloma in older adults: Gaining ground with geriatric assessment. <i>Journal of Geriatric Oncology</i> , 2017, 8, 1-7.	1.0	25

#	ARTICLE	IF	CITATIONS
153	Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. <i>Leukemia</i> , 2017, 31, 115-122.	7.2	61
154	The role of SLAMF7 in multiple myeloma: impact on therapy. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 67-75.	3.0	13
155	Evaluation of low-dose thalidomide as induction and maintenance therapy in patients with multiple myeloma not eligible for stem cell transplantation. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e138-e143.	1.1	2
156	Proteasome inhibitors in cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 417-433.	27.6	675
157	Racial differences in the survival of elderly patients with multiple myeloma in pre- and post-novel agent era. <i>Journal of Geriatric Oncology</i> , 2017, 8, 125-127.	1.0	1
158	Fresh perspectives on treatment and moments of clarity. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 73-74.	27.6	9
159	The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5. <i>Oncology and Therapy</i> , 2017, 5, 31-40.	2.6	3
160	Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma. <i>Annals of Hematology</i> , 2017, 96, 431-439.	1.8	25
161	The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: results from the population-based PROFILES registry. <i>Annals of Hematology</i> , 2017, 96, 653-663.	1.8	7
162	Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience. <i>Drugs</i> , 2017, 77, 505-520.	10.9	150
163	Impact of induction treatment before autologous stem cell transplantation on long-term outcome in patients with newly diagnosed multiple myeloma. <i>European Journal of Haematology</i> , 2017, 98, 569-576.	2.2	4
164	Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study. <i>British Journal of Haematology</i> , 2017, 177, 441-448.	2.5	21
165	How I manage the toxicities of myeloma drugs. <i>Blood</i> , 2017, 129, 2359-2367.	1.4	44
166	Treating Multiple Myeloma Patients With Oral Therapies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 243-251.	0.4	30
167	Trends in overall survival and costs of multiple myeloma, 2000–2014. <i>Leukemia</i> , 2017, 31, 1915-1921.	7.2	257
168	Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial. <i>British Journal of Haematology</i> , 2017, 176, 743-749.	2.5	14
169	Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy. <i>British Journal of Haematology</i> , 2017, 177, 254-262.	2.5	6
170	Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan. <i>Cancer Science</i> , 2017, 108, 461-468.	3.9	16

#	ARTICLE	IF	CITATIONS
171	Study design for vulnerable older adults with multiple myeloma. <i>Journal of Geriatric Oncology</i> , 2017, 8, 162-164.	1.0	0
172	The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. <i>Clinical Cancer Research</i> , 2017, 23, 3980-3993.	7.0	71
173	Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey. <i>Annals of Hematology</i> , 2017, 96, 987-993.	1.8	17
174	Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 571-582.	2.5	45
175	Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017, 28, iv52-iv61.	1.2	619
176	Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma. <i>European Journal of Haematology</i> , 2017, 98, 289-295.	2.2	2
177	Nuclear medicine imaging of multiple myeloma, particularly in the relapsed setting. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 332-341.	6.4	12
178	Recognition of early mortality in multiple myeloma by a prediction matrix. <i>American Journal of Hematology</i> , 2017, 92, 915-923.	4.1	31
179	Where are we now with the treatment of multiple myeloma?. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 461-462.	27.6	11
180	Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial. <i>Leukemia</i> , 2017, 31, 2435-2442.	7.2	18
181	Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. <i>New England Journal of Medicine</i> , 2017, 376, 1311-1320.	27.0	924
182	Response Assessment in Myeloma: Practical Manual on Consistent Reporting in an Era of Dramatic Therapeutic Advances. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1193-1202.	2.0	14
183	Mechanisms of Resistance in Multiple Myeloma. <i>Handbook of Experimental Pharmacology</i> , 2017, 249, 251-288.	1.8	20
184	Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment. <i>Blood Cancer Journal</i> , 2017, 7, e543-e543.	6.2	10
185	Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2016. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 329-339.	0.4	29
186	Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2017, 389, 519-527.	13.7	684
187	Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials. <i>American Journal of Hematology</i> , 2017, 92, 244-250.	4.1	19
188	Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis. <i>Leukemia</i> , 2017, 31, 1727-1734.	7.2	41

#	ARTICLE	IF	CITATIONS
189	IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM). <i>Leukemia</i> , 2017, 31, 1363-1367.	7.2	38
190	Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist. <i>Therapeutic Advances in Hematology</i> , 2017, 8, 55-70.	2.5	31
191	A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma. <i>Blood</i> , 2017, 129, 383-385.	1.4	51
192	Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Haematology</i> , 2017, 4, e534-e543.	4.6	31
193	Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses. <i>Targeted Oncology</i> , 2017, 12, 643-654.	3.6	19
194	Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. <i>Lancet Haematology</i> , 2017, 4, e431-e442.	4.6	132
195	Updated analysis of CALGB (Alliance) 100104. <i>Lancet Haematology</i> , 2017, 4, e404-e405.	4.6	0
196	The treatment of paraprotein-related kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2017, 26, 477-483.	2.0	4
197	Renal insufficiency in patients with multiple myeloma. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 151-158.	0.5	0
198	Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice?. <i>Blood</i> , 2017, 130, 859-866.	1.4	60
199	Multiple myeloma. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17046.	30.5	812
200	How I treat myeloma with new agents. <i>Blood</i> , 2017, 130, 1507-1513.	1.4	65
201	Elderly patients with multiple myeloma: towards a frailty approach?. <i>Current Opinion in Oncology</i> , 2017, 29, 315-321.	2.4	77
202	Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity. <i>British Journal of Haematology</i> , 2017, 179, 399-409.	2.5	39
203	The proteasome and proteasome inhibitors in multiple myeloma. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 561-584.	5.9	229
205	Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1975-1985.	1.8	10
206	Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation. <i>Nature Communications</i> , 2017, 8, 1613.	12.8	45
207	Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 575-583.e2.	0.4	71

#	ARTICLE	IF	CITATIONS
208	How I treat first relapse of myeloma. <i>Blood</i> , 2017, 130, 963-973.	1.4	58
209	Targeted therapy and maintenance in myeloma. <i>British Medical Bulletin</i> , 2017, 122, 163-178.	6.9	0
210	Strategies for Selecting the Optimal Treatment in Newly Diagnosed Multiple Myeloma Patients. <i>Seminars in Oncology Nursing</i> , 2017, 33, 254-264.	1.5	3
212	Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide. <i>Clinical Pharmacokinetics</i> , 2017, 56, 139-152.	3.5	65
213	Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 81-88.	4.7	37
214	High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges. <i>Leukemia and Lymphoma</i> , 2017, 58, 1283-1296.	1.3	6
215	Second primary malignancies in multiple myeloma: an overview and IMWG consensus. <i>Annals of Oncology</i> , 2017, 28, 228-245.	1.2	102
216	Observational study of multiple myeloma in Latin America. <i>Annals of Hematology</i> , 2017, 96, 65-72.	1.8	29
217	Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide. <i>Leukemia and Lymphoma</i> , 2017, 58, 560-568.	1.3	9
218	Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study. <i>European Journal of Cancer</i> , 2017, 70, 22-33.	2.8	28
219	Practical Considerations in Managing Relapsed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 69-77.	0.4	12
220	A phase 1/2 trial of lenalidomide and dexamethasone in adult patients with refractory/relapsed acute lymphoblastic leukemia. <i>Hematology</i> , 2017, 22, 217-223.	1.5	0
221	Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network. <i>Leukemia</i> , 2017, , .	7.2	11
223	Fixed duration vs continuous therapy in multiple myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 212-222.	2.5	24
224	New developments in the management of relapsed/refractory multiple myeloma – the role of ixazomib. <i>Journal of Blood Medicine</i> , 2017, Volume 8, 107-121.	1.7	19
225	Comparison of Minimal Residual Disease Detection by Multiparameter Flow Cytometry, ASO-qPCR, Droplet Digital PCR, and Deep Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation. <i>Journal of Clinical Medicine</i> , 2017, 6, 91.	2.4	29
226	Cost-Effectiveness of Novel Agents in Medicare Patients with Multiple Myeloma: Findings from a U.S. Payer's Perspective. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, 831-843.	0.9	14
227	Short-Course Lenalidomide Plus Low-Dose Dexamethasone in the Treatment of Newly Diagnosed Multiple Myeloma"A Single-Centre Pragmatic Study. <i>Current Oncology</i> , 2017, 24, 361-367.	2.2	1

#	ARTICLE	IF	CITATIONS
228	Fasting regulates EGR1 and protects from glucose- and dexamethasone-dependent sensitization to chemotherapy. <i>PLoS Biology</i> , 2017, 15, e2001951.	5.6	45
229	News from ASH 2016 about the multiple myeloma. <i>Hematologie</i> , 2017, 23, 25-32.	0.0	0
230	Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study. <i>Journal of Hematology and Oncology</i> , 2017, 10, 137.	17.0	56
231	ELOTUZUMAB FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA, WITH SPECIAL REFERENCE TO ITS MODES OF ACTION AND SLAMF7 SIGNALING. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2017, 10, e2018014.	1.3	15
232	Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma. <i>Antibodies</i> , 2017, 6, 18.	2.5	12
233	Should minimal residual disease negativity be the end point of myeloma therapy?. <i>Blood Advances</i> , 2017, 1, 517-521.	5.2	10
234	Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 3279-3289.	1.6	535
235	Myeloma in Elderly Patients: When Less Is More and More Is More. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 575-585.	3.8	16
236	Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression. <i>Oncotarget</i> , 2017, 8, 24031-24044.	1.8	77
237	Targeting MYC in multiple myeloma. <i>Leukemia</i> , 2018, 32, 1295-1306.	7.2	89
238	Ixazomib in the management of relapsed multiple myeloma. <i>Future Oncology</i> , 2018, 14, 2013-2020.	2.4	7
239	Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role. <i>Leukemia</i> , 2018, 32, 2427-2434.	7.2	8
240	Phase II Clinical Trial of Lenalidomide and Dexamethasone Therapy in Japanese Elderly Patients With Newly Diagnosed Multiple Myeloma to Determine Optimal Plasma Concentration of Lenalidomide. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 301-309.	2.0	9
241	Lenalidomide versus lenalidomide+Âdexamethasone prolonged treatment after secondÂline lenalidomide+Âdexamethasone induction in multiple myeloma. <i>Cancer Medicine</i> , 2018, 7, 2256-2268.	2.8	1
242	Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1357-1366.	2.5	8
244	Treatment of Transplant Eligible Patients with Multiple Myeloma. <i>Hematologic Malignancies</i> , 2018, , 29-60.	0.2	1
245	Treatment of Elderly Patients with Multiple Myeloma. <i>Hematologic Malignancies</i> , 2018, , 61-71.	0.2	1
246	Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 152-160.	0.4	34

#	ARTICLE	IF	CITATIONS
247	Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop. <i>Leukemia and Lymphoma</i> , 2018, 59, 2305-2317.	1.3	18
248	Current developments in immunotherapy in the treatment of multiple myeloma. <i>Cancer</i> , 2018, 124, 2075-2085.	4.1	49
249	The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe. <i>Expert Review of Hematology</i> , 2018, 11, 219-237.	2.2	28
250	Myeloma Cells Are Activated in Bone Marrow Microenvironment by the CD180/MD-1 Complex, Which Senses Lipopolysaccharide. <i>Cancer Research</i> , 2018, 78, 1766-1778.	0.9	23
251	Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. <i>Leukemia</i> , 2018, 32, 979-985.	7.2	25
252	Triplet vs. doublet drug regimens for managing multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 137-149.	1.8	21
253	A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus – clinical significance and possible mechanisms: a case report. <i>Journal of Medical Case Reports</i> , 2018, 12, 40.	0.8	5
254	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2018, 32, 1542-1560.	7.2	68
255	Frail Patients with Newly Diagnosed Multiple Myeloma. , 2018, , 539-549.		1
256	Bortezomib maintenance therapy in transplant-ineligible myeloma patients who plateaued after bortezomib-based induction therapy: a multicenter phase II clinical trial. <i>International Journal of Hematology</i> , 2018, 108, 39-46.	1.6	6
257	Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents. <i>Leukemia</i> , 2018, 32, 1267-1276.	7.2	18
258	Novel Treatments for Multiple Myeloma: What Role Do They Have in Older Adults?. <i>Drugs and Aging</i> , 2018, 35, 289-302.	2.7	2
259	Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone. <i>Leukemia and Lymphoma</i> , 2018, 59, 398-405.	1.3	13
260	Population Pharmacokinetics of Lenalidomide in Healthy Volunteers and Patients With Hematologic Malignancies. <i>Clinical Pharmacology in Drug Development</i> , 2018, 7, 465-473.	1.6	11
261	Treat or palliate: outcomes of very elderly myeloma patients. <i>Haematologica</i> , 2018, 103, e32-e34.	3.5	15
262	Managing multiple myeloma in elderly patients. <i>Leukemia and Lymphoma</i> , 2018, 59, 1300-1311.	1.3	18
263	Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. <i>Leukemia</i> , 2018, 32, 712-718.	7.2	27
264	A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making: Multiple Myeloma. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 67-76.	4.7	14

#	ARTICLE	IF	CITATIONS
265	From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. <i>Haematologica</i> , 2018, 103, 197-211.	3.5	110
266	Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. <i>New England Journal of Medicine</i> , 2018, 378, 518-528.	27.0	747
267	Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. <i>Blood</i> , 2018, 131, 301-310.	1.4	216
268	Treatment of Multiple Myeloma in Elderly Patients: A Review of Literature and Practice Guidelines. <i>Cureus</i> , 2018, 10, e3669.	0.5	6
269	Treatment of Relapsed Myeloma in a Patient With Renal Insufficiency. <i>Journal of Clinical Oncology</i> , 2018, 36, 2012-2016.	1.6	2
271	Practical Considerations for Antibodies in Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 667-674.	3.8	6
272	Clinical Efficacy of a Novel Therapeutic Principle, Anakinosis. <i>Frontiers in Pharmacology</i> , 2018, 9, 1357.	3.5	26
273	Mechanisms of Drug Resistance in Cancer Therapy. <i>Handbook of Experimental Pharmacology</i> , 2018, , .	1.8	1
274	Multiple Myeloma: Front Line Therapy and Autologous Stem Cell Transplantation. <i>Annals of the National Academy of Medical Sciences (India)</i> , 2018, 54, 096-105.	0.3	0
276	Identifying Educational Needs and Practice Gaps of European Hematologists and Hematology Nurses in the Treatment and Management of Multiple Myeloma. <i>HemaSphere</i> , 2018, 2, e33.	2.7	2
277	Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. <i>Blood Cancer Journal</i> , 2018, 8, 109.	6.2	170
278	The power of proteasome inhibition in multiple myeloma. <i>Expert Review of Proteomics</i> , 2018, 15, 1033-1052.	3.0	33
279	Ixazomib for the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1949-1968.	1.8	42
280	Lenalidomide-based response-adapted therapy for older adults without high risk myeloma. <i>British Journal of Haematology</i> , 2018, 184, 735-743.	2.5	2
281	Special problems in the management of elderly patients with multiple myeloma. <i>European Journal of Internal Medicine</i> , 2018, 58, 64-69.	2.2	1
282	Daratumumab plus bortezomib and dexamethasone <i>versus</i> bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. <i>Haematologica</i> , 2018, 103, 2079-2087.	3.5	225
283	Society of Hematologic Oncology State of the Art Update and Next Questions: Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 693-702.	0.4	5
284	Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 132, 9-16.	4.4	13

#	ARTICLE	IF	CITATIONS
285	Combined Use of Ninjin'yoeito Improves Subjective Fatigue Caused by Lenalidomide in Patients With Multiple Myeloma: A Retrospective Study. <i>Frontiers in Nutrition</i> , 2018, 5, 72.	3.7	8
286	Association of CD117 and HLA-DR expression with shorter overall survival and/or progression-free survival in patients with multiple myeloma treated with bortezomib and thalidomide combination treatment without transplantation. <i>Oncology Letters</i> , 2018, 16, 5655-5666.	1.8	7
287	Triplet therapies – the new standard of care for multiple myeloma: how to manage common toxicities. <i>Expert Review of Hematology</i> , 2018, 11, 957-973.	2.2	7
288	Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study. <i>Annals of Hematology</i> , 2018, 97, 2455-2463.	1.8	16
289	Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1. <i>Frontiers in Immunology</i> , 2018, 9, 1822.	4.8	46
290	Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 88-96.	2.5	18
291	Survival of ethnic and racial minority patients with multiple myeloma treated with newer medications. <i>Blood Advances</i> , 2018, 2, 116-119.	5.2	19
292	Timing of treatment of smoldering myeloma: delay until progression. <i>Blood Advances</i> , 2018, 2, 3050-3053.	5.2	5
293	Management of Multiple Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 624-627.	4.9	10
294	A predictive model for risk of early grade 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. <i>Leukemia</i> , 2018, 32, 1404-1413.	7.2	53
295	Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival. <i>Annals of Hematology</i> , 2018, 97, 1671-1682.	1.8	17
296	Determining treatment intensity in elderly patients with multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 917-930.	2.4	10
297	Twice-weekly ixazomib in combination with lenalidomide+dexamethasone in patients with newly diagnosed multiple myeloma. <i>British Journal of Haematology</i> , 2018, 182, 231-244.	2.5	30
298	Maintenance and continuous therapy for multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 751-764.	2.4	10
299	Long-Term Efficacy of Maintenance Therapy for Multiple Myeloma: A Quantitative Synthesis of 22 Randomized Controlled Trials. <i>Frontiers in Pharmacology</i> , 2018, 9, 430.	3.5	3
300	Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients. <i>Neoplasma</i> , 2018, 65, 585-591.	1.6	1
301	Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry. <i>Clinical Therapeutics</i> , 2018, 40, 1193-1202.e1.	2.5	10
302	Plasma Cell Neoplasms. , 2018, , 1381-1418.e1.		4

#	ARTICLE	IF	CITATIONS
303	Real life management of patients hospitalized with multiple myeloma in France. PLoS ONE, 2018, 13, e0196596.	2.5	8
304	Update on the role of lenalidomide in patients with multiple myeloma. Therapeutic Advances in Hematology, 2018, 9, 175-190.	2.5	42
305	Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma. Journal of Medical Economics, 2018, 21, 793-798.	2.1	8
306	Cancer research in the United States: A critical review of current status and proposal for alternative models. Cancer, 2018, 124, 2881-2889.	4.1	14
307	A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. British Journal of Haematology, 2018, 182, 222-230.	2.5	118
308	Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. Journal of Hematology and Oncology, 2018, 11, 49.	17.0	33
309	Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib+lenalidomide+dexamethasone versus placebo+lenalidomide+dexamethasone in relapsed/refractory multiple myeloma. American Journal of Hematology, 2018, 93, 985-993.	4.1	41
310	The safety of bortezomib for the treatment of multiple myeloma. Expert Opinion on Drug Safety, 2018, 17, 953-962.	2.4	64
311	Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management. American Journal of Hematology, 2018, 93, 1091-1110.	4.1	166
312	Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia, 2018, 32, 1697-1712.	7.2	83
313	GFR estimation in lenalidomide treatment of multiple myeloma patients: a prospective cohort study. Clinical and Experimental Nephrology, 2019, 23, 199-206.	1.6	1
314	Development of a prognostic model for overall survival in multiple myeloma using the Connect ^{MM} MM Patient Registry. British Journal of Haematology, 2019, 187, 602-614.	2.5	11
315	Upfront treatment for newly diagnosed transplant-ineligible multiple myeloma patients: A systematic review and network meta-analysis of 14,533 patients over 29 randomized clinical trials. Critical Reviews in Oncology/Hematology, 2019, 143, 102-116.	4.4	10
316	Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 645-655.	0.4	15
317	Cost-effectiveness of lenalidomide plus low-dose dexamethasone for newly diagnosed multiple myeloma patients ineligible for stem cell transplantation in China. Journal of Comparative Effectiveness Research, 2019, 8, 979-992.	1.4	3
318	Frontline treatment of elderly non transplant-eligible multiple myeloma patients using CyBorD with or without thalidomide-based consolidation: a retrospective multi-centre analysis of real-world data. British Journal of Haematology, 2019, 187, 470-477.	2.5	12
319	Report of phase I and II trials of melphalan, prednisolone, and thalidomide triplet combination therapy versus melphalan and prednisolone doublet combination therapy in Japanese patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplantation. International Journal of Hematology, 2019, 110, 447-457.	1.6	1
320	The immunomodulatory-drug, lenalidomide, sustains and enhances interferon- γ production by human plasmacytoid dendritic cells. Journal of Blood Medicine, 2019, Volume 10, 217-226.	1.7	9

#	ARTICLE	IF	CITATIONS
321	Inflammasome inhibitors: promising therapeutic approaches against cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 64.	17.0	61
322	Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network. <i>Journal of Clinical Medicine</i> , 2019, 8, 877.	2.4	20
323	What are the implications of cost for myeloma therapy?. <i>Expert Review of Hematology</i> , 2019, 12, 1005-1009.	2.2	1
324	The evolving role of maintenance therapy following autologous stem cell transplantation in multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 889-898.	2.4	6
325	Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis. <i>Cancers</i> , 2019, 11, 1735.	3.7	7
326	Reducing infection-related morbidity and mortality in patients with myeloma. <i>Lancet Oncology</i> , The, 2019, 20, 1633-1635.	10.7	3
327	Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations. <i>Blood Reviews</i> , 2019, 34, 84-94.	5.7	35
329	Daratumumab added to standard of care in patients with newly diagnosed multiple myeloma: A network meta-analysis. <i>European Journal of Haematology</i> , 2019, 103, 542-551.	2.2	6
330	Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 31-38.	2.3	15
331	Mechanism of Action and Novel IMiD-Based Compounds and Combinations in Multiple Myeloma. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 19-31.	2.0	7
332	Thalidomide maintenance therapy in Japanese myeloma patients: a multicenter, phase II clinical trial (COMET study). <i>International Journal of Hematology</i> , 2019, 109, 409-417.	1.6	3
333	Methodological aspects of health-related quality of life measurement and analysis in patients with multiple myeloma. <i>British Journal of Haematology</i> , 2019, 185, 11-24.	2.5	13
334	Management of Newly Diagnosed Elderly Multiple Myeloma Patients. <i>Current Oncology Reports</i> , 2019, 21, 64.	4.0	16
335	Initial Therapy in Older Patients with Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 380, 2172-2173.	27.0	4
336	Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. <i>New England Journal of Medicine</i> , 2019, 380, 2104-2115.	27.0	684
337	Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 522-530.e1.	0.4	47
338	Immunomodulatory drugs in the treatment of multiple myeloma. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 695-702.	1.3	17
339	Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. <i>Blood</i> , 2019, 134, 421-431.	1.4	110

#	ARTICLE	IF	CITATIONS
340	Influence of ABCB1 polymorphisms on the pharmacokinetics and toxicity of lenalidomide in patients with multiple myeloma. <i>Medical Oncology</i> , 2019, 36, 55.	2.5	6
341	Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, 853-861.	4.1	33
342	Impact of prior bortezomib therapy on the incidence of lenalidomide-induced skin rash in multiple myeloma: a propensity score-matched multi-institutional cohort study. <i>Leukemia and Lymphoma</i> , 2019, 60, 2975-2981.	1.3	7
343	Expert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 187-196.	2.3	8
344	Induction Therapy for Newly Diagnosed Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e176-e186.	3.8	28
345	Approach to the Older Adult With Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 500-518.	3.8	36
346	Treatment Outcomes in Patients With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem-Cell Transplantation: Systematic Review and Network Meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e478-e488.	0.4	10
347	Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide. <i>Blood Cancer Journal</i> , 2019, 9, 38.	6.2	52
348	Therapy-related myeloid neoplasms after treatment for plasma-cell disorders. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 54-64.	1.7	12
349	Updates on Hematologic Malignancies in the Older Adult: Focus on Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Multiple Myeloma. <i>Current Oncology Reports</i> , 2019, 21, 35.	4.0	5
350	Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2019, 133, 1953-1963.	1.4	94
351	Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study. <i>American Journal of Hematology</i> , 2019, 94, 635-640.	4.1	43
352	Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 137, 18-26.	4.4	12
353	Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies. <i>European Journal of Haematology</i> , 2019, 102, 494-503.	2.2	11
354	JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-1. Multiple myeloma (MM). <i>International Journal of Hematology</i> , 2019, 109, 509-538.	1.6	27
355	Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2019, 37, 1228-1263.	1.6	190
356	Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries. <i>Annals of Hematology</i> , 2019, 98, 941-949.	1.8	9
357	Addition of Cyclophosphamide "On Demand" to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma: A Retrospective Review of a Single-center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e195-e203.	0.4	4

#	ARTICLE	IF	CITATIONS
358	Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 70-82.	2.3	16
359	The pharmacologic management of multiple myeloma in older adults. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 887-902.	1.8	11
360	Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France. <i>Advances in Hematology</i> , 2019, 2019, 1-12.	1.0	9
361	Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 2-10.	2.0	10
362	Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone. <i>Blood Advances</i> , 2019, 3, 4095-4103.	5.2	17
363	Supervised and home-based physical exercise in patients newly diagnosed with multiple myeloma—a randomized controlled feasibility study. <i>Pilot and Feasibility Studies</i> , 2019, 5, 130.	1.2	21
364	Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis. <i>The Cochrane Library</i> , 2020, 2020, .	2.8	21
365	<p>Prognostic Significance Of The Inflammatory Index-Based Scoring System In Patients Preliminarily Diagnosed With Multiple Myeloma In The Bortezomib-Based Chemotherapy Era</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 9409-9420.	1.9	8
366	Daratumumab in untreated newly diagnosed multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071989487.	2.5	31
367	Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing. <i>Blood</i> , 2019, 133, 652-659.	1.4	41
368	Lenalidomide as maintenance for every newly diagnosed patient with multiple myeloma. <i>Lancet Oncology</i> , The, 2019, 20, 5-6.	10.7	7
369	Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 57-73.	10.7	245
370	All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>European Journal of Cancer</i> , 2019, 106, 89-98.	2.8	25
371	3â€Bromopyruvate as a potent anticancer therapy in honor and memory of the late Professor AndrÃ© Coffeau. <i>Yeast</i> , 2019, 36, 211-221.	1.7	13
372	Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma. <i>International Journal of Cancer</i> , 2019, 145, 559-568.	5.1	10
373	Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis. <i>Haematologica</i> , 2019, 104, 1026-1035.	3.5	17
374	Clinical characteristics and prognosis of immunoglobulin D myeloma in the novel agent era. <i>Annals of Hematology</i> , 2019, 98, 963-970.	1.8	15
375	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet</i> , The, 2019, 393, 253-264.	13.7	187

#	ARTICLE	IF	CITATIONS
376	Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. <i>Haematologica</i> , 2020, 105, 1650-1659.	3.5	19
377	Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e30-e37.	0.4	75
378	A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. <i>Leukemia</i> , 2020, 34, 224-233.	7.2	122
379	Minimal residual disease in multiple myeloma 2019. <i>Advances in Cell and Gene Therapy</i> , 2020, 3, e71.	0.9	1
380	First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. <i>Haematologica</i> , 2020, 105, 1074-1080.	3.5	16
381	Solitary Plasmacytoma Treated by Lenalidomide-Dexamethasone in Combination with Radiation Therapy: Clinical Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 589-596.	0.8	19
382	A matching-adjusted indirect treatment comparison (MAIC) of daratumumabâ€“bortezomibâ€“melphalanâ€“prednisone (D-VMP) versus lenalidomideâ€“dexamethasone continuous (Rd continuous), lenalidomideâ€“dexamethasone 18 months (Rd 18), and melphalanâ€“prednisoneâ€“thalidomide (MPT). <i>Leukemia and Lymphoma</i> , 2020, 61, 714-720.	1.3	3
383	Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis. <i>Leukemia and Lymphoma</i> , 2020, 61, 668-679.	1.3	5
384	Current treatment patterns and medical costs for multiple myeloma in Japan: a cross-sectional analysis of a health insurance claims database. <i>Journal of Medical Economics</i> , 2020, 23, 166-173.	2.1	12
385	Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan. <i>International Journal of Hematology</i> , 2020, 111, 65-74.	1.6	11
386	Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. <i>Haematologica</i> , 2020, 105, 1937-1947.	3.5	29
387	Venous thromboembolism risk with contemporary lenalidomideâ€“based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis. <i>Cancer</i> , 2020, 126, 1640-1650.	4.1	28
388	Multiple Myeloma and Related Disorders. , 2020, , 1884-1910.e7.		4
389	Cast nephropathy. , 2020, , 59-66.e3.		0
390	Clinical outcomes with fixed-duration therapy (UK real-world data) compared with continuous lenalidomide and low-dose dexamethasone therapy (FIRST trial; MM-020) for transplant-ineligible patients with newly-diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020, 61, 732-736.	1.3	3
391	Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 137-145.	1.8	5
392	Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 4030-4041.	1.6	56
393	Multiple myeloma current treatment algorithms. <i>Blood Cancer Journal</i> , 2020, 10, 94.	6.2	178

#	ARTICLE	IF	CITATIONS
394	Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis. <i>Advances in Therapy</i> , 2020, 37, 4996-5009.	2.9	2
395	Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients. <i>Cancer Medicine</i> , 2020, 9, 8923-8930.	2.8	4
396	Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e850-e857.	0.4	1
398	Quality of patient-reported outcome reporting in randomised controlled trials of haematological malignancies according to international quality standards: a systematic review. <i>Lancet Haematology</i> , 2020, 7, e892-e901.	4.6	23
399	Sequencing multiple myeloma therapies with and after antibody therapies. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 248-258.	2.5	10
400	Multiple myeloma: the (r)evolution of current therapy and a glance into future. <i>Haematologica</i> , 2020, 105, 2358-2367.	3.5	73
401	Maintenance therapy in transplant ineligible adults with newly diagnosed multiple myeloma: A systematic review and meta-analysis. <i>European Journal of Haematology</i> , 2020, 105, 626-634.	2.2	3
402	Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. <i>Blood</i> , 2020, 136, 2513-2523.	1.4	56
403	Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review. <i>Expert Review of Hematology</i> , 2020, 13, 943-958.	2.2	16
404	Immunotherapeutic and Targeted Approaches in Multiple Myeloma. <i>ImmunoTargets and Therapy</i> , 2020, Volume 9, 201-215.	5.8	14
405	Diagnostic and Therapeutic Challenges in the Management of Intermediate and Frail Elderly Multiple Myeloma Patients. <i>Cancers</i> , 2020, 12, 3106.	3.7	12
406	Low-dose lenalidomide and dexamethasone therapy after melphalan-prednisolone induction in elderly patients with newly diagnosed multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 2351-2356.	1.8	0
407	Pembrolizumab plus lenalidomide and dexamethasone in treatment-naïve multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients. <i>International Journal of Hematology</i> , 2020, 112, 640-649.	1.6	2
408	How I Manage Frontline Transplant-Ineligible Multiple Myeloma. <i>Hematology Reports</i> , 2020, 12, 8956.	0.8	6
409	Emerging immunotherapies in multiple myeloma. <i>BMJ</i> , 2020, 370, m3176.	6.0	62
410	Management of Frail Older Adults with Newly Diagnosed Multiple Myeloma – Moving Toward a Personalized Approach. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S76-S80.	0.4	2
411	Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy. <i>Cancer Management and Research</i> , 2020, Volume 12, 7891-7903.	1.9	32
413	Recommendations on the management of multiple myeloma in 2020. <i>Acta Clinica Belgica</i> , 2020, , 1-17.	1.2	1

#	ARTICLE	IF	CITATIONS
415	Real-world treatment patterns and outcomes in non-transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom. <i>European Journal of Haematology</i> , 2020, 105, 308-325.	2.2	11
416	Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study. <i>Blood Cancer Journal</i> , 2020, 10, 58.	6.2	9
417	An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment – validation of official dosing guidelines. <i>Leukemia and Lymphoma</i> , 2020, 61, 1860-1868.	1.3	1
418	Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effects. <i>Leukemia and Lymphoma</i> , 2020, 61, 2365-2374.	1.3	4
419	Infection-related morbidity in a large study of transplant non-eligible newly diagnosed myeloma patients treated with UK standard of care. <i>Haematologica</i> , 2020, 105, e474-479.	3.5	10
420	<p>Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide</p>. <i>Clinical Interventions in Aging</i> , 2020, Volume 15, 619-633.	2.9	10
421	Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1285-1292.	1.0	14
422	Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current Therapies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e734-e751.	0.4	2
423	Defining the vulnerable patient with myeloma – a frailty position paper of the European Myeloma Network. <i>Leukemia</i> , 2020, 34, 2285-2294.	7.2	45
424	Evolution of diagnostic workup and treatment for multiple myeloma 2013 – 2019. <i>European Journal of Haematology</i> , 2020, 105, 434-448.	2.2	2
425	Network meta-analysis of first-line treatments in transplant-ineligible multiple myeloma patients. <i>European Journal of Haematology</i> , 2020, 105, 56-65.	2.2	9
426	Immunotherapy in Multiple Myeloma. <i>Cells</i> , 2020, 9, 601.	4.1	27
427	Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. <i>American Journal of Hematology</i> , 2020, 95, 548-567.	4.1	507
428	Use of Curcumin in Multiple Myeloma patients intolerant of steroid therapy. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 739-744.	0.5	14
429	Myeloma care adaptations in the UK during SARS-CoV-2 pandemic: Challenges and measurable outcomes. <i>European Journal of Haematology</i> , 2020, 105, 662-666.	2.2	2
430	MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma. <i>Blood</i> , 2020, 136, 2557-2573.	1.4	33
431	Management of newly diagnosed transplant ineligible multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020, 61, 2549-2560.	1.3	2
432	Toxicities of novel therapies for hematologic malignancies. <i>Expert Review of Hematology</i> , 2020, 13, 241-257.	2.2	2

#	ARTICLE	IF	CITATIONS
433	The safety of current and emerging therapies for multiple myeloma. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 269-279.	2.4	6
434	Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma. <i>Expert Review of Hematology</i> , 2020, 13, 375-392.	2.2	5
435	Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 17.	6.2	75
436	Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients. <i>PLoS ONE</i> , 2020, 15, e0229469.	2.5	7
437	Treatment and disease-related complications in multiple myeloma: Implications for survivorship. <i>American Journal of Hematology</i> , 2020, 95, 672-690.	4.1	22
438	Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e221-e238.	0.4	9
439	Elevated eosinophil level predicted long time to next treatment in relapsed or refractory myeloma patients treated with lenalidomide. <i>Cancer Medicine</i> , 2020, 9, 1694-1702.	2.8	5
440	Modern treatments and future directions for newly diagnosed multiple myeloma patients. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101151.	1.7	6
441	Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study. <i>International Journal of Hematology</i> , 2020, 111, 692-701.	1.6	9
442	Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1063-1072.	1.8	4
443	Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1850-1859.	1.3	11
444	EHA evaluation of the ESMO Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. <i>ESMO Open</i> , 2020, 5, e000611.	4.5	10
445	Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSC 21.13 trial. <i>Haematologica</i> , 2020, 105, 2879-2882.	3.5	20
446	The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1709-1725.	1.8	12
447	Newly Diagnosed Myeloma in 2020. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e144-e158.	3.8	9
448	Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma. <i>Cancer Research</i> , 2020, 80, 2031-2044.	0.9	36
449	Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies. <i>Haematologica</i> , 2021, 106, 1079-1085.	3.5	12
450	Advances & future prospects in newly diagnosed multiple myeloma patients. <i>Advances in Cell and Gene Therapy</i> , 2021, 4, .	0.9	1

#	ARTICLE	IF	CITATIONS
451	Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2021, 56, 368-375.	2.4	8
452	Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial. <i>British Journal of Haematology</i> , 2021, 192, 853-868.	2.5	14
453	Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age. <i>Leukemia</i> , 2021, 35, 809-822.	7.2	7
454	Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 227-237.	1.6	22
455	Disparities in treatment patterns and outcomes among younger and older adults with newly diagnosed multiple myeloma: A population-based study. <i>Journal of Geriatric Oncology</i> , 2021, 12, 508-514.	1.0	12
456	Outcomes of lenalidomide or bortezomib-based regimens in older patients with plasma cell myeloma. <i>American Journal of Hematology</i> , 2021, 96, 14-22.	4.1	4
457	Optimal Designs for Multi-Arm Phase II/III Drug Development Programs. <i>Statistics in Biopharmaceutical Research</i> , 2021, 13, 71-81.	0.8	2
458	The Role of Targeted Therapy in Multiple Myeloma. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2021, , 1-15.	0.1	0
459	Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients. <i>Blood Cancer Journal</i> , 2021, 11, 5.	6.2	11
460	Original Versus Generic Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Comparison of Effectivity and Adverse Events. <i>Turkish Journal of Haematology</i> , 2021, 38, 41-48.	0.5	0
461	Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 1.	6.2	57
462	Renal insufficiency in multiple myeloma: a systematic review and meta-analysis of all randomized trials from 2005 to 2019. <i>Leukemia and Lymphoma</i> , 2021, 62, 1386-1395.	1.3	6
463	Prognostic and Predictive Factors in Newly Diagnosed Multiple Myeloma Patients with Early Mortality with Prediction Matrix and Three and Five-Year Overall Survival. , 0, , .		0
464	Old and new generation immunomodulatory drugs in multiple myeloma. <i>Panminerva Medica</i> , 2021, 62, 207-219.	0.8	4
465	Analysis of risk factors for lenalidomide-associated skin rash in patients with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2021, 62, 1405-1410.	1.3	4
466	Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities. <i>Frontiers in Oncology</i> , 2020, 10, 606368.	2.8	23
468	Efficacy and tolerability of VCD chemotherapy in a UK real-world dataset of elderly transplant-ineligible newly diagnosed myeloma patients. <i>European Journal of Haematology</i> , 2021, 106, 563-573.	2.2	1
469	Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database. <i>British Journal of Haematology</i> , 2021, 193, 532-541.	2.5	9

#	ARTICLE	IF	CITATIONS
471	Carfilzomib in combination with daratumumab in the management of relapsed multiple myeloma. <i>Future Oncology</i> , 2021, 17, 993-998.	2.4	1
472	Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2021, 137, 3616-3628.	1.4	48
473	Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMM. <i>Cancers</i> , 2021, 13, 1322.	3.7	6
474	Cancer therapies based on targeted protein degradation – lessons learned with lenalidomide. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 401-417.	27.6	69
475	Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 63.	6.2	11
476	Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline. <i>British Journal of Haematology</i> , 2021, 193, 245-268.	2.5	24
477	Immunomodulators in newly diagnosed multiple myeloma: current and future concepts. <i>Expert Review of Hematology</i> , 2021, 14, 365-376.	2.2	4
478	Cost-Effectiveness Analysis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma. <i>Frontiers in Pharmacology</i> , 2021, 12, 608685.	3.5	4
479	Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021, 32, 309-322.	1.2	316
480	Evolution of Treatment Paradigms in Newly Diagnosed Multiple Myeloma. <i>Drugs</i> , 2021, 81, 825-840.	10.9	6
481	The impact of changed treatment patterns in multiple myeloma on health care utilisation and costs, myeloma complications, and survival: A population-based comparison between two time periods in Denmark. <i>European Journal of Haematology</i> , 2021, 107, 63-73.	2.2	3
482	Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma. <i>Annals of Hematology</i> , 2021, 100, 1769-1778.	1.8	9
483	Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1119-1128.	1.6	23
484	Chromosome 1q21 abnormalities in multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 83.	6.2	64
485	Association of Morbid Progression With Overall Survival Among Patients With Multiple Myeloma: Validation of the Progression-free Survival Endpoint. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 345-354.e4.	0.4	4
486	Current and Novel Alkylators in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 2465.	3.7	12
487	Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. <i>Blood Cancer Journal</i> , 2021, 11, 101.	6.2	14
488	Maintenance Strategies for Myeloma. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 231-238.	2.0	0

#	ARTICLE	IF	CITATIONS
489	Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 405.e1-405.e6.	1.2	4
490	Transplant-ineligible newly diagnosed multiple myeloma: Current and future approaches to clinical care: A Young International Society of Geriatric Oncology Review Paper. <i>Journal of Geriatric Oncology</i> , 2021, 12, 499-507.	1.0	7
491	Role of ARK5 in cancer and other diseases (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 697.	1.8	9
492	Simple desensitization protocol for multiple myeloma patients with lenalidomide-induced skin rash: Case series. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 1792-1795.	1.5	5
493	A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16 trial. <i>British Journal of Haematology</i> , 2021, 194, 580-586.	2.5	5
494	Healthcare resource utilisation and sickness absence in newly diagnosed multiple myeloma patients who did not undergo autologous stem cell transplantation: Trends in Sweden with the changing treatment landscape. <i>European Journal of Haematology</i> , 2021, 107, 92-103.	2.2	1
495	Induction Therapy Strategies in the Transplant-Ineligible Population. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 196-200.	2.0	1
496	Advances in Management for Older Adults With Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2021, 39, 2102-2114.	1.6	24
497	Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs. <i>Blood</i> , 2021, 137, 2987-2989.	1.4	1
498	Dose intensity and treatment duration of bortezomib in transplant-ineligible newly diagnosed multiple myeloma. <i>European Journal of Haematology</i> , 2021, 107, 246-254.	2.2	2
499	Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods. <i>Leukemia</i> , 2021, 35, 3600-3603.	7.2	11
500	Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2021, 137, 3027-3036.	1.4	40
501	Real-world analysis of patient characteristics, treatment outcomes, and healthcare resource utilization across Europe in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation who received lenalidomide- or bortezomib-based regimens. <i>Leukemia and Lymphoma</i> , 2021, 62, 2492-2501.	1.3	6
502	Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 191-203.	2.5	3
503	Updates in the management of relapsed/refractory multiple myeloma. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1477-1490.	0.9	2
504	Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data. <i>European Journal of Haematology</i> , 2021, 107, 466-474.	2.2	1
505	Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma. <i>Frontiers in Oncology</i> , 2021, 11, 703233.	2.8	6
506	Using Surrogate Endpoints in Adaptive Designs with Delayed Treatment Effect. <i>Statistics in Biopharmaceutical Research</i> , 2022, 14, 661-670.	0.8	6

#	ARTICLE	IF	CITATIONS
507	Prediction Model for Cereblon Expression in Bone Marrow Plasma Cells Based on Blood Markers in Multiple Myeloma Patients. <i>Frontiers in Oncology</i> , 2021, 11, 687361.	2.8	0
508	Anti-body building: The exercise of advancing immune based myeloma therapies. <i>Blood Reviews</i> , 2021, 48, 100789.	5.7	2
509	Phase II clinical trial of personalized VCD-VTD sequential therapy using the Vulnerable Elders Survey-13 (VES-13) for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>Annals of Hematology</i> , 2021, 100, 2745-2754.	1.8	2
510	Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2021, 62, 3011-3018.	1.3	2
511	Epidemiology, genetics and treatment of multiple myeloma and precursor diseases. <i>International Journal of Cancer</i> , 2021, 149, 1980-1996.	5.1	25
512	RAR β activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway. <i>Blood</i> , 2022, 139, 59-72.	1.4	6
513	Real-Life Experience With First-Line Therapy Bortezomib Plus Melphalan and Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma Ineligible for High Dose Chemotherapy With Autologous Stem-Cell Transplantation. <i>Frontiers in Medicine</i> , 2021, 8, 712070.	2.6	4
514	Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive Care: Recommendation of the Canadian Myeloma Research Group (formerly Myeloma Canada Research) <i>Tj ETQq1 1 0.784314 rgBT₁₁ Overlook</i> e41-e56.	0.4	11
515	Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk features. <i>Current Problems in Cancer</i> , 2021, 46, 100788.	2.0	1
516	Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma. <i>Cancers</i> , 2021, 13, 4666.	3.7	10
517	A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). <i>American Journal of Hematology</i> , 2021, 96, 1595-1603.	4.1	15
518	Treatment patterns and outcomes among nontransplant newly diagnosed multiple myeloma patients in Spain. <i>Future Oncology</i> , 2021, 17, 3465-3476.	2.4	1
519	Geriatric assessments and frailty scores in multiple myeloma patients. <i>Current Opinion in Oncology</i> , 2021, Publish Ahead of Print, 648-657.	2.4	16
520	Recent therapeutic approaches in myeloma. , 2022, , 1019-1029.		0
521	Bone remodeling: analysis, discussion, and perspectives. , 2021, , 207-218.		0
522	Current diagnosis, risk stratification and treatment paradigms in newly diagnosed multiple myeloma. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100444.	1.7	5
524	Validation, Multivariate Modeling, and the Construction of Heat-Map Prediction Matrices for Survival in the Context of Missing Data. <i>ICSA Book Series in Statistics</i> , 2018, , 353-374.	0.2	1
525	A comparison between the assessments of progression-free survival by local investigators versus blinded independent central reviews in phase III oncology trials. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1083-1092.	1.9	11

#	ARTICLE	IF	CITATIONS
526	Targeting MYC in multiple myeloma. <i>Leukemia</i> , 0, , .	7.2	2
527	Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. <i>HemaSphere</i> , 2021, 5, e528.	2.7	45
528	Realistic Lenalidomide Dose Adjustment Strategy for Transplant-Ineligible Elderly Patients with Relapsed/Refractory Multiple Myeloma: Japanese Real-World Experience. <i>Acta Haematologica</i> , 2017, 138, 55-60.	1.4	9
529	The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma. <i>Singapore Medical Journal</i> , 2017, 58, 55-71.	0.6	6
530	Thromboprophylaxis in Multiple Myeloma Patients Treated with Lenalidomide - a Systematic Review. <i>Blood</i> , 2015, 126, 2321-2321.	1.4	1
531	Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma. <i>Blood Advances</i> , 2020, 4, 2163-2171.	5.2	21
532	Best of 2017 in Multiple Myeloma. , 2018, 15, .		1
533	Efficacy and Safety of Danshen Compound Tablets in Preventing Thalidomide-Associated Thromboembolism in Patients with Multiple Myeloma: A Multicenter Retrospective Study. <i>Medical Science Monitor</i> , 2016, 22, 3835-3842.	1.1	6
534	Myeloma in Elderly Patients: When Less Is More and More Is More. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 575-585.	3.8	20
535	Novel mechanisms of action for immunomodulatory drugs (IMiDs) against multiple myeloma: from a tragedy to a therapy. <i>International Journal of Hematology & Therapy</i> , 2016, 2, 1-6.	0.1	2
536	A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma. <i>Oncotarget</i> , 2017, 8, 37605-37618.	1.8	6
537	Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties. <i>Oncotarget</i> , 2017, 8, 53053-53067.	1.8	27
538	Chromosomal instability and acquired drug resistance in multiple myeloma. <i>Oncotarget</i> , 2017, 8, 78234-78244.	1.8	21
539	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrazji plazmocytowych na rok 2018/2019. <i>Acta Haematologica Polonica</i> , 2018, 49, 157-206.	0.3	4
540	Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma. <i>Journal of Clinical Medicine</i> , 2020, 9, 3120.	2.4	35
541	Recent advances in multiple myeloma: a Korean perspective. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 820-834.	1.7	22
542	Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 809-819.	1.7	8
543	Multiple Myeloma, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1398-1435.	4.9	55

#	ARTICLE	IF	CITATIONS
544	Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1685-1717.	4.9	138
545	Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients. Expert Review of Hematology, 2021, , 1-14.	2.2	1
546	Clinical trial participation improves survival outcomes by increasing availability of new therapeutic agents in multiple myeloma. British Journal of Haematology, 2022, 196, 1117-1120.	2.5	2
547	Transitioning to an All Oral Therapy for Multiple Myeloma with the Novel Proteasome Inhibitor Ixazomib. , 2015, 12, .		0
548	Treatment of elderly patients with myeloma. , 2015, , 41-63.		0
550	VI. Standard Treatment for Multiple Myeloma. The Journal of the Japanese Society of Internal Medicine, 2016, 105, 1238-1245.	0.0	0
551	Advances in the management of multiple myeloma. Journal of Community and Supportive Oncology, 2016, 14, 232-238.	0.1	0
552	Plasmazellneoplasien. , 2017, , 511-533.		0
554	Treatment of t(4;14) and del(17p) in Multiple Myeloma. , 2018, , 59-76.		0
555	Multiples Myelom beim alten und geriatrischen Patienten. , 2018, , 1-10.		0
556	Risk Stratification in Newly Diagnosed Transplant Ineligible Multiple Myeloma. , 2018, , 37-58.		0
557	Multiples Myelom beim alten und geriatrischen Patienten. , 2018, , 261-270.		0
558	GuÃ©rison du myÃ©lome multiple : un objectif envisageable Ã© court terme ?. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 953-961.	0.0	0
559	Nursing support during treatment of multiple myeloma with proteasome inhibitors. Cancer Nursing Practice, 2018, , .	0.0	0
561	Moving Toward Continuous Therapy in Multiple Myeloma. Clinical Hematology International, 2019, 1, 189.	1.7	5
562	Plasma cell myeloma and related monoclonal gammopathies. , 2020, , 5310-5324.		0
563	Multiples Myelom und andere plasmazellulÃ©re Erkrankungen. , 2020, , 63-73.		0
564	Antitumor effect of lenalidomide in malignant glioma cell lines. Oncology Reports, 2020, 43, 1580-1590.	2.6	6

#	ARTICLE	IF	CITATIONS
565	Multiple Myeloma: Current Advances and Future Directions. Kitakanto Medical Journal, 2020, 70, 175-185.	0.0	1
566	Factors Associated with Dose Modification of Lenalidomide Plus Dexamethasone Therapy in Multiple Myeloma. Biological and Pharmaceutical Bulletin, 2020, 43, 1253-1258.	1.4	1
567	Multiple Myeloma in Older Adults. , 2020, , 549-565.		0
568	Multiple Myeloma with a Special Focus on Precision Medicine. Healthbook TIMES Oncology Hematology, 2020, , .	0.1	0
569	Plasmazellneoplasien. , 2020, , 541-564.		0
570	ERKRANKUNGEN DES BLUTES UND DES GERINNLINGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. , 2020, , B-1-B30-3.		0
571	Lenalidomide (Revlimid): A Thalidomide Analogue in Combination With Dexamethasone For the Treatment of All Patients With Multiple Myeloma. P and T, 2016, 41, 308-13.	0.9	6
573	Revlimid (Lenalidomide) Now FDA Approved as First-Line Therapy for Patients with Multiple Myeloma. American Health and Drug Benefits, 2016, 9, 140-3.	0.5	7
574	Therapeutic Leap for Multiple Myeloma in 2015: Unprecedented FDA Drug Approvals. American Health and Drug Benefits, 2016, 9, 36-9.	0.5	1
575	The Paraprotein - an Enduring Biomarker. Clinical Biochemist Reviews, 2019, 40, 5-22.	3.3	16
580	Preceding bortezomib administration for a certain period reduces the risk of lenalidomide-induced skin rash. Journal of Clinical Pharmacy and Therapeutics, 2021, , .	1.5	0
581	Daratumumab-based therapies in transplant-ineligible patients with untreated multiple myeloma and hepatic dysfunction: A systematic review of subgroup analyses. Journal of Oncology Pharmacy Practice, 2023, 29, 155-161.	0.9	1
582	SOHO State of the Art Updates and Next Questions: Treatment of Older, Vulnerable Adults with Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 279-286.	0.4	1
583	Real-world outcomes of pomalidomide therapy after lenalidomide induction in relapsed/refractory multiple myeloma. Future Oncology, 2022, 18, 553-564.	2.4	4
584	Nonproportional Hazards – An Evaluation of the MaxCombo Test in Cancer Clinical Trials. Statistics in Biopharmaceutical Research, 2023, 15, 300-309.	0.8	5
585	Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients. PLoS ONE, 2022, 17, e0262388.	2.5	3
586	Current Treatment Approaches to Newly Diagnosed Multiple Myeloma. Oncology Research and Treatment, 2021, 44, 690-699.	1.2	11
587	Management of Multiple Myeloma in Older Patients. European Medical Journal Hematology, 0, , 69-81.	0.0	1

#	ARTICLE	IF	CITATIONS
588	Examining health related quality of life outcomes in multiple myeloma: Past and future perspectives. <i>Seminars in Oncology</i> , 2022, , .	2.2	2
589	Tumor Reduction in Multiple Myeloma: New Concepts for New Therapeutics. <i>Frontiers in Oncology</i> , 2021, 11, 800309.	2.8	1
590	Patient-Reported Outcomes in Randomized Controlled Trials of Patients with Multiple Myeloma: A Systematic Literature Review of Studies Published Between 2014 and 2021. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 442-459.	0.4	7
591	Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients. <i>Leukemia</i> , 2022, 36, 613-624.	7.2	11
592	Advantages and drawbacks of dexamethasone in glioblastoma multiforme. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103625.	4.4	16
593	Drug resistance and minimal residual disease in multiple myeloma. <i>Cancer Drug Resistance (Alhambra,)</i> Tj ETQq1 1 0,784314,3rgBT /Over	2.1	1
594	Belantamab mafodotin for relapsed or refractory multiple myeloma. <i>Journal of Oncology Pharmacy Practice</i> , 2022, , 107815522210862.	0.9	0
595	Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 608-617.	0.4	4
596	Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database. <i>Current Oncology</i> , 2022, 29, 1575-1582.	2.2	3
597	Underrepresentation of Black participants and adverse events in clinical trials of lenalidomide for myeloma. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103644.	4.4	1
598	Prognostic role of the ratio of natural killer cells to regulatory T cells in patients with multiple myeloma treated with lenalidomide and dexamethasone. <i>Experimental Hematology</i> , 2022, 110, 60-68.	0.4	2
599	Treatment of older adult or frail patients with multiple myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 46-54.	2.5	5
600	Daratumumab for the Treatment of Multiple Myeloma: A Review of Clinical Applicability and Operational Considerations. <i>Annals of Pharmacotherapy</i> , 2022, 56, 927-940.	1.9	8
601	Ikaros Proteins in Tumor: Current Perspectives and New Developments. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 788440.	3.5	5
615	Drug Targeting and Conventional Treatment of Multiple Myeloma: Analysis of Target Specific Nanotherapies in Disease Models. <i>Current Drug Therapy</i> , 2022, 17, .	0.3	0
616	Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results. <i>Frontiers in Oncology</i> , 2022, 12, .	2.8	12
617	Transient Viral Activation in Human T Cell Leukemia Virus Type 1-Infected Macaques Treated With Pomalidomide. <i>Frontiers in Medicine</i> , 2022, 9, .	2.6	4
618	Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , the, 2022, 9, e403-e414.	4.6	23

#	ARTICLE	IF	CITATIONS
619	Elotuzumab: no benefit for older patients with newly diagnosed multiple myeloma. <i>Lancet Haematology</i> , 2022, , .	4.6	0
620	Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2022, 97, 1086-1107.	4.1	208
621	Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Uncontrolled Oncology Trials: A Comprehensive Review of the Literature. <i>Frontiers in Pharmacology</i> , 2022, 13, .	3.5	1
622	Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. <i>Blood Cancer Discovery</i> , 2022, 3, 273-284.	5.0	24
623	Using surrogate information to improve confirmatory platform trial with sample size re-estimation. <i>Journal of Biopharmaceutical Statistics</i> , 0, , 1-20.	0.8	1
624	Healthcare Resource Utilization and Cost of Patients with Multiple Myeloma in Germany: A Retrospective Claims Data Analysis. <i>Pharmacoeconomics - Open</i> , 2022, 6, 619-628.	1.8	4
625	Evidence-based Recommendations for Induction and Maintenance Treatment of Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients. <i>Critical Reviews in Oncology/Hematology</i> , 2022, , 103744.	4.4	3
626	Low cerebrospinal fluid-to-plasma ratios of orally administered lenalidomide mediated by its low cell membrane permeability in patients with hematologic malignancies. <i>Annals of Hematology</i> , 0, , .	1.8	0
627	What's Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma. <i>Targeted Oncology</i> , 2022, 17, 383-405.	3.6	7
628	Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e1000-e1008.	0.4	1
629	Recent advances in the management of older adults with newly diagnosed multiple myeloma in Japan. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	1.3	1
630	Treatment of Patients with Newly-Diagnosed Multiple Myeloma. , 0, , .		0
631	Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review. <i>British Journal of Haematology</i> , 2022, 199, 190-204.	2.5	9
632	Myeloma and Leukemia. , 2023, , 503-528.		0
634	Treatment horizon in multiple myeloma. <i>European Journal of Haematology</i> , 2022, 109, 425-440.	2.2	6
635	Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies. <i>JCO Global Oncology</i> , 2022, , .	1.8	2
636	Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	5
637	Fasting-mimicking diet cycles reduce neuroinflammation to attenuate cognitive decline in Alzheimer's models. <i>Cell Reports</i> , 2022, 40, 111417.	6.4	15

#	ARTICLE	IF	CITATIONS
638	A stratified therapeutic model incorporated with studies on regulatory B cells for elderly patients with newly diagnosed multiple myeloma. <i>Cancer Medicine</i> , 2023, 12, 3054-3067.	2.8	4
639	Improved survival in myeloma patients—a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden. <i>Haematologica</i> , 2023, 108, 1640-1651.	3.5	7
641	Effectiveness of D-Rd program in the first line therapy of a 75-year-old female patient with multiple myeloma with high-risk cytogenetics. <i>Clinical observation.</i> , 2022, 2, 28-35.		1
642	Comparing the efficacy of different dexamethasone regimens for maintenance treatment of multiple myeloma in standard-risk patients non-eligible for transplantation. <i>World Journal of Clinical Cases</i> , 0, 10, 11712-11725.	0.8	0
643	Comparison between ixazomib+cyclophosphamide+dexamethasone regimen and ixazomib+dexamethasone regimen for elderly and frail patients having newly diagnosed multiple myeloma. <i>Cancer Medicine</i> , 2023, 12, 6523-6535.	2.8	1
644	The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed/refractory disease. <i>Expert Review of Proteomics</i> , 2022, 19, 235-246.	3.0	3
645	Oral Therapies for Multiple Myeloma. <i>Touch Reviews in Oncology & Haematology</i> , 2022, 18, 139.	0.2	0
646	The Pivotal Role of Proteasome Inhibition in Myeloma Treatment. <i>European Medical Journal Hematology</i> , 0, , 2-10.	0.0	0
647	Savings associated with therapeutic appropriateness for patients with relapsed refractory multiple myeloma and high cytogenetic risk diagnosed by FISH test. <i>AboutOpen</i> , 0, 9, 105-111.	0.2	0
648	Randomized phase III study of daratumumab versus bortezomib plus daratumumab as maintenance therapy after D-MPB for transplant-ineligible patients with untreated multiple myeloma (JCOG1911.) <i>Tj ETQq1 1 0.784314 rgBT /Over</i>	0.2	0
649	Newly diagnosed multiple myeloma: making sense of the menu. <i>Hematology American Society of Hematology Education Program</i> , 2022, 2022, 539-550.	2.5	1
650	Drug-induced olfactory and gustatory dysfunction: Analysis of FDA adverse events reporting system. <i>Auris Nasus Larynx</i> , 2023, 50, 558-564.	1.2	2
651	How I treat multiple myeloma in geriatric patients. <i>Blood</i> , 2024, 143, 224-232.	1.4	5
652	Predictors of lenalidomide maintenance duration after autologous stem cell transplant in patients with multiple myeloma. <i>Journal of Oncology Pharmacy Practice</i> , 0, , 107815522211509.	0.9	0
653	First Line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Recommendations from the Canadian Myeloma Research Group Consensus Guideline Consortium. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2023, 23, 340-354.	0.4	0
654	Multiple Myeloma and Renal Failure. <i>European Medical Journal Oncology</i> , 0, , 65-69.	0.0	0
655	Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2023, 23, 446-455.e4.	0.4	2
656	Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy. <i>Blood Cancer Journal</i> , 2023, 13, .	6.2	5

#	ARTICLE	IF	CITATIONS
657	A real-world data analysis of predictors of early mortality after a diagnosis of multiple myeloma. <i>Cancer</i> , 2023, 129, 2023-2034.	4.1	0
658	Real world outcomes of lenalidomide or bortezomib maintenance in patients with multiple myeloma not undergoing stem cell transplantation. <i>Annals of Hematology</i> , 2023, 102, 1171-1184.	1.8	0
659	Targeted protein degrader development for cancer: advances, challenges, and opportunities. <i>Trends in Pharmacological Sciences</i> , 2023, 44, 303-317.	8.7	9
660	Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma. <i>Anti-Cancer Drugs</i> , 0, Publish Ahead of Print, .	1.4	0
661	SETDB1 induces lenalidomide resistance in multiple myeloma cells via epithelial-mesenchymal transition and PI3K/AKT pathway activation. <i>Experimental and Therapeutic Medicine</i> , 2023, 25, .	1.8	1
662	ML-based sequential analysis to assist selection between VMP and RD for newly diagnosed multiple myeloma. <i>Npj Precision Oncology</i> , 2023, 7, .	5.4	4
663	Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2023, , .	0.4	1
664	New Strategies for the Treatment of Older Myeloma Patients. <i>Cancers</i> , 2023, 15, 2693.	3.7	0
665	Radiotherapy in Combination with Systemic Therapy for Multiple Myeloma—A Critical Toxicity Evaluation in the Modern Treatment Era. <i>Cancers</i> , 2023, 15, 2909.	3.7	2
666	Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 187, 104040.	4.4	2
667	Multiple myeloma management: What comes after lenalidomide-based therapy?. , 0, , .		0
668	Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis. <i>Blood Cancer Journal</i> , 2023, 13, .	6.2	3
669	Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting. <i>Biomedicines</i> , 2023, 11, 2087.	3.2	1
670	Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma. <i>Blood</i> , 2023, 142, 1518-1528.	1.4	4
671	Editorial: Proteomic and metabolic reprogramming in myeloma cells within the tumor microenvironment. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
672	Lenalidomide plus Dexamethasone Combination as First-Line Oral Therapy of Multiple Myeloma Patients: A Unicentric Real-Life Study. <i>Cancers</i> , 2023, 15, 4036.	3.7	1
673	Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13. <i>HemaSphere</i> , 2023, 7, e940.	2.7	0
674	Risk of thromboembolic events associated with different multiple myeloma regimens in Taiwan: a nested case-control study. <i>Journal of Thrombosis and Thrombolysis</i> , 2023, 56, 578-587.	2.1	1

#	ARTICLE	IF	CITATIONS
676	Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma. <i>Haematologica</i> , 0, , .	3.5	0
677	Advanced practice nurse management in multiple myeloma treated with oral therapy. <i>Bulletin Du Cancer</i> , 2023, 110, 1251-1259.	1.6	0
679	The age-dependent changes in risk weights of the prognostic factors for multiple myeloma. <i>Hematology</i> , 2023, 28, .	1.5	0
680	A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group. <i>Annals of Hematology</i> , 0, , .	1.8	0
681	Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs. <i>Journal of Clinical Oncology</i> , 2023, 41, 4968-4972.	1.6	10
682	IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?. <i>Life</i> , 2023, 13, 2229.	2.4	0
684	Lenalidomide use in multiple myeloma (Review). <i>Molecular and Clinical Oncology</i> , 2023, 20, .	1.0	1
685	Data Monitoring Committees and clinical trials: From scientific justification to organisation. <i>Therapie</i> , 2024, 79, 111-121.	1.0	0
686	Isatuximab in the treatment of refractory and relapsed multiple myeloma: literature review and case report. <i>Oncogematologiya</i> , 2023, 18, 90-103.	0.3	0
687	Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders. <i>European Journal of Medicinal Chemistry</i> , 2024, 265, 116041.	5.5	0
688	Management of Newly Diagnosed Multiple Myeloma Today, and in the Future. <i>Hematology/Oncology Clinics of North America</i> , 2024, 38, 441-459.	2.2	0
689	Translocation t(14;16) in multiple myeloma: gangster or just part of the gang?. <i>Blood Cancer Journal</i> , 2024, 14, .	6.2	0
691	Considerations for the treatment of frail multiple myeloma patients. <i>Clinical Hematology International</i> , 2024, 6, .	1.7	0
692	Plasmazell-Neoplasien. , 2024, , 575-599.		0
693	Randomized comparison between <sc>KTd</sc> and <sc>KRd</sc> induction therapy followed by maintenance therapy with K or observation in transplant-eligible patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2024, 99, 1008-1011.	4.1	0
694	A structured oral chemotherapy teaching tool to improve adherence in adults with multiple myeloma: A pilot randomized controlled trial. <i>Journal of Geriatric Oncology</i> , 2024, 15, 101735.	1.0	0
695	Performance Characteristics and Limitations of the Available Assays for the Detection and Quantitation of Monoclonal Free Light Chains and New Emerging Methodologies. <i>Antibodies</i> , 2024, 13, 19.	2.5	0
696	Daratumumab Treatment for "Truly Frail" Elderly Myeloma Patients. <i>Life</i> , 2024, 14, 389.	2.4	0

#	ARTICLE	IF	CITATIONS
697	Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece. Clinical Lymphoma, Myeloma and Leukemia, 2024, , .	0.4	0